Mylan (NASDAQ:MYL) had its price target upped by investment analysts at Mizuho from $25.00 to $27.00 in a research note issued on Tuesday, July 30th, The Fly reports. The firm presently has a “neutral” rating on the stock. Mizuho’s price target suggests a potential upside of 53.32% from the company’s previous close.
A number of other brokerages have also recently weighed in on MYL. Barclays assumed coverage on Mylan in a research report on Tuesday, June 11th. They set an “overweight” rating and a $26.00 price target on the stock. Wolfe Research assumed coverage on Mylan in a research report on Friday, July 19th. They issued an “outperform” rating and a $27.00 target price on the stock. BMO Capital Markets set a $36.00 target price on Mylan and gave the company a “buy” rating in a research report on Wednesday, May 8th. Raymond James set a $31.00 target price on Mylan and gave the company a “buy” rating in a research report on Wednesday, May 8th. Finally, Wells Fargo & Co cut Mylan from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $33.00 to $22.00 in a research report on Tuesday, May 7th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $30.43.
Shares of MYL opened at $17.61 on Tuesday. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.37. The stock has a 50-day moving average price of $19.10 and a 200 day moving average price of $23.57. Mylan has a one year low of $16.63 and a one year high of $39.59. The company has a market capitalization of $9.87 billion, a P/E ratio of 3.84, a P/E/G ratio of 0.91 and a beta of 1.77.
In related news, Director Richard A. Mark bought 4,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were bought at an average cost of $20.97 per share, for a total transaction of $83,880.00. Following the completion of the acquisition, the director now directly owns 4,000 shares in the company, valued at $83,880. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Robert J. Coury bought 49,859 shares of the business’s stock in a transaction on Friday, August 2nd. The shares were bought at an average price of $20.06 per share, for a total transaction of $1,000,171.54. Following the completion of the acquisition, the director now owns 947,194 shares of the company’s stock, valued at $19,000,711.64. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 63,859 shares of company stock valued at $1,275,152. 0.81% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Global Retirement Partners LLC increased its stake in shares of Mylan by 107.1% in the first quarter. Global Retirement Partners LLC now owns 967 shares of the company’s stock worth $27,000 after purchasing an additional 500 shares during the period. Pinnacle Bank increased its stake in shares of Mylan by 66.4% in the first quarter. Pinnacle Bank now owns 1,060 shares of the company’s stock worth $30,000 after purchasing an additional 423 shares during the period. Advisory Services Network LLC grew its position in Mylan by 170.0% during the second quarter. Advisory Services Network LLC now owns 1,520 shares of the company’s stock worth $29,000 after buying an additional 957 shares in the last quarter. Mascoma Wealth Management LLC acquired a new stake in Mylan during the first quarter worth about $47,000. Finally, NuWave Investment Management LLC grew its position in Mylan by 1,111.0% during the second quarter. NuWave Investment Management LLC now owns 2,192 shares of the company’s stock worth $42,000 after buying an additional 2,011 shares in the last quarter. Institutional investors own 83.54% of the company’s stock.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Recommended Story: Economic Bubble
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.